Parkman Healthcare Partners’s Natera NTRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-50,751
Closed -$2.25M 101
2023
Q3
$2.25M Sell
50,751
-24,288
-32% -$1.24M 0.41% 68
2023
Q2
$3.65M Sell
75,039
-50,004
-40% -$2.55M 0.63% 51
2023
Q1
$6.94M Buy
125,043
+71,551
+134% +$3.43M 1.51% 29
2022
Q4
$2.15M Sell
53,492
-51,709
-49% -$2.13M 0.57% 55
2022
Q3
$4.61M Buy
105,201
+31,154
+42% +$1.48M 1.31% 24
2022
Q2
$2.62M Sell
74,047
-55,897
-43% -$2.07M 0.97% 35
2022
Q1
$5.29M Buy
129,944
+5,394
+4% +$324K 1.55% 23
2021
Q4
$11.6M Buy
124,550
+34,503
+38% +$3.58M 2.57% 11
2021
Q3
$10M Sell
90,047
-30,500
-25% -$3.5M 2.54% 10
2021
Q2
$13.7M Sell
120,547
-19,346
-14% -$1.98M 2.99% 9
2021
Q1
$14.2M Buy
139,893
+19,026
+16% +$2.08M 3.3% 5
2020
Q4
$12M Sell
120,867
-54,294
-31% -$4.54M 3.08% 6
2020
Q3
$12.7M Buy
175,161
+25,028
+17% +$1.42M 3.35% 4
2020
Q2
$7.49M Buy
150,133
+65,000
+76% +$2.61M 2.11% 14
2020
Q1
$2.54M Sell
85,133
-65,710
-44% -$2.2M 1.18% 29
2019
Q4
$5.08M Buy
+150,843
New +$5.56M 1.47% 26

Other funds holding NTRA

Parkman Healthcare Partners's NTRA Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Natera (NTRA) in Q4 2023, closing a stake of 50,751 shares — an estimated $2.25M sold.

Parkman Healthcare Partners first reported a position in NTRA in Q4 2019 and held it in 16 quarters. The position peaked at $14.2M in Q1 2021. 351 funds tracked by Wall St. Rank hold NTRA as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Natera position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 50,751 Natera shares in Q4 2023, an estimated $2.25M.
  • Parkman Healthcare Partners first reported a position in Natera in Q4 2019 and held it in 16 quarters.
  • Parkman Healthcare Partners's Natera position peaked at $14.2M in Q1 2021.
  • 351 funds tracked by Wall St. Rank held Natera as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.